Humana (NYSE:HUM) Earns Buy Rating from Guggenheim

Humana (NYSE:HUM)‘s stock had its “buy” rating reissued by stock analysts at Guggenheim in a report issued on Friday,Benzinga reports.

Several other equities analysts also recently weighed in on HUM. Truist Financial cut their price target on shares of Humana from $280.00 to $260.00 and set a “hold” rating on the stock in a report on Wednesday, July 16th. Mizuho set a $300.00 price objective on Humana in a research report on Friday. Piper Sandler lowered their price objective on Humana from $288.00 to $272.00 and set a “neutral” rating on the stock in a research report on Thursday, July 31st. Wall Street Zen lowered Humana from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, Royal Bank Of Canada upped their price objective on Humana from $283.00 to $322.00 and gave the stock an “outperform” rating in a research report on Thursday, August 21st. Seven research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $291.21.

Humana Price Performance

Shares of NYSE:HUM opened at $284.00 on Friday. Humana has a twelve month low of $206.87 and a twelve month high of $315.35. The company’s 50 day moving average is $274.76 and its 200 day moving average is $257.35. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69. The company has a market cap of $34.16 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.67 and a beta of 0.42.

Humana (NYSE:HUM) last issued its quarterly earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a return on equity of 13.67% and a net margin of 1.28%.The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter last year, the company posted $6.96 EPS. Humana’s quarterly revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts forecast that Humana will post 16.47 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Janney Montgomery Scott LLC purchased a new position in shares of Humana during the 1st quarter valued at approximately $1,309,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Humana by 16.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,136,538 shares of the insurance provider’s stock valued at $300,728,000 after buying an additional 158,528 shares in the last quarter. Focus Partners Wealth lifted its position in shares of Humana by 104.2% during the 1st quarter. Focus Partners Wealth now owns 6,429 shares of the insurance provider’s stock valued at $1,701,000 after buying an additional 3,281 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in Humana by 2.4% in the 1st quarter. Envestnet Asset Management Inc. now owns 125,684 shares of the insurance provider’s stock valued at $33,256,000 after purchasing an additional 2,950 shares in the last quarter. Finally, Circle Wealth Management LLC purchased a new position in Humana in the 1st quarter valued at $425,000. Hedge funds and other institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.